ArticleTherapeutic advances in medical oncology2018

Preclinical and phase I clinical studies of KW-2450, a dual IGF-1R/IR tyrosine kinase inhibitor, in combination with lapatinib and letrozole.

Hiroshi Umehara et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.